As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Many play into fads with scant evidence to back up enthusiasts’ claims, medical experts say. Some influencers encourage their ...

Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...

A DAILY weight loss pill is a safer alternative to gastric bypass surgery, makers say. The tablet does the same job by making people feel full for longer. Its developers say the treatment is a ...

IT ONCE boasted over five million subscribers and saw one million of us stepping onto the scales every year. But ...

Ozempic was originally approved by the Food and Drug Administration (FDA) to treat people with Type 2 diabetes, who risk ...

These GLP-1 drugs have proven effective at helping people lose weight—and are showing promise for a host of other indications ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...